THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus

R.A Furie,V Strand,C Gordon,M Petri,S Bongardt,C Galateanu,D.J Wallace,W Koetse

doi:10.1136/annrheumdis-2014-eular.1854

THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus

R.A Furie, V Strand + Show 6 more

https://doi.org/10.1136/annrheumdis-2014-eular.1854

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2014
Citations: 1

Affiliation: Long Island Jewish Medical Center, University of Birmingham, Johns Hopkins Medicine, Johns Hopkins University, UCB Pharma (Belgium)

#British Isles Lupus Assessment Group #Patient Global Assessment Scores + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundEpratuzumab is a monoclonal antibody that targets CD22 on B cells. In EMBLEM™ (dose-ranging Phase 2b study [NCT00624351]), and its open-label extension (OLE; SL0008 [NCT00660881]), epratuzumab produced sustained and clinically...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.